Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) director Sangeeta N. Bhatia filed a Form 144 notice on November 16, 2026, disclosing a proposed sale of 271 shares of common stock through Fidelity Brokerage Services LLC.

Key Highlights

  • Seller: Sangeeta N. Bhatia, identified in the filing as a director of Vertex Pharmaceuticals Inc / MA.
  • Shares proposed for sale: 271 shares of common stock, with an aggregate market value of $148,470.06 as stated in the filing.
  • Shares outstanding: The filing reports 253,537,674 shares of common stock outstanding.
  • Approximate date of sale: November 16, 2026, on the NASDAQ exchange.
  • Source of shares: The 271 shares were acquired on May 1, 2025, through restricted stock vesting from the issuer, with payment characterized as compensation.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of August 13, 2026.
  • Prior sales: The filing states "Nothing to Report" for securities sold during the past three months.

Bhatia's Proposed Rule 144 Sale: Share Source and Plan Details

According to the filing, Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals Inc / MA (NASDAQ:VRTX), submitted a Form 144 notice of proposed sale of securities. The filing identifies Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, as the broker through which the 271 shares of common stock are proposed to be sold. The aggregate market value of the shares is listed as $148,470.06.

The filing discloses that the 271 shares were acquired on May 1, 2025, through a restricted stock vesting transaction from the issuer, with the nature of payment listed as compensation. No prior sales of Vertex securities were reported by Bhatia during the three months preceding the notice. The filing also notes reliance on a Rule 10b5-1 trading plan, with an adoption date of August 13, 2026. The notice was signed by Margaret Campbell as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Sangeeta N. Bhatia.

The filing was submitted as a live filing with a notice date of November 16, 2026. Vertex Pharmaceuticals is headquartered at 50 Northern Avenue, Boston, Massachusetts 02210, with SEC File Number 000-19319, according to the issuer information section of the form.

What Was Disclosed

A Form 144 notice was filed on November 16, 2026, by Vertex Pharmaceuticals director Sangeeta N. Bhatia, covering a proposed sale of 271 shares of common stock with an aggregate market value of $148,470.06, acquired through restricted stock vesting on May 1, 2025.